Document Detail

Treating fatigue.
MedLine Citation:
PMID:  17686346     Owner:  NLM     Status:  MEDLINE    
Fatigue is recognized as one of the most disabling and common symptoms of MS. However, no universal consensus has been reached regarding a formal definition for fatigue, and its mechanisms and causes are not understood. This review summarizes important research in this field and recommends a multidisciplinary approach to managing MS patients with fatigue. Such an approach should include proven pharmaceutical and non-pharmaceutical treatments.
Y Lapierre; S Hum
Related Documents :
24639576 - Perceptual awareness and its neural basis: bridging experimental and theoretical paradi...
14982706 - Menthol pharmacology and its potential impact on cigarette smoking behavior.
14660136 - Where to for tobacco regulation: time for new approaches?
22969746 - Advancing our understanding of the link between statistical learning and language acqui...
22774866 - The meaning of work among chinese university students: findings from prototype research...
24653326 - A project to enable tissue donation for research purposes.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  International MS journal / MS Forum     Volume:  14     ISSN:  1352-8963     ISO Abbreviation:  Int MS J     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-08-09     Completed Date:  2007-10-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9804403     Medline TA:  Int MS J     Country:  England    
Other Details:
Languages:  eng     Pagination:  64-71     Citation Subset:  IM    
Montreal Neurological Hospital/Institute, 3801 University, Montreal, Quebec, Canada H3A 2B4.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amantadine / therapeutic use*
Central Nervous System Stimulants / therapeutic use*
Diagnosis, Differential
Dopamine Agents / therapeutic use*
Evidence-Based Medicine
Fatigue / drug therapy,  etiology,  therapy*
Multiple Sclerosis / physiopathology*
Patient Care Team
Pemoline / therapeutic use*
Reg. No./Substance:
0/Central Nervous System Stimulants; 0/Dopamine Agents; 2152-34-3/Pemoline; 768-94-5/Amantadine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Confirming the MS diagnosis.
Next Document:  Intravenous ketamine attenuates injection pain and arterial pressure changes during the induction of...